The shelf registration is tied to Life Technologies' acquisition late last year of BioTrove.
The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.
Helicos will use the funds for R&D efforts and general corporate purposes. Its shares tumbled in response to the offering.
The firm will apply the proceeds primarily to its drug development efforts.
The firm sold 5.4 million shares at $7 per share.
The firm will offer 4.7 million shares at a price of $7 per share.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.